The Drug Regulatory Authority Pakistan (DRAP) canceled the licenses of five local pharmaceutical companies and suspended the licenses of 12 others in a major crackdown against substandard medicines today.
According to media reports, the companies whose licenses have been revoked are in Islamabad, Peshawar, Lahore, Karachi, and Hyderabad.
The DRAP has also suspended the licenses of five companies in Sindh, five in Khyber Pakhtunkhwa, and one each in Balochistan and Islamabad under the DRAP Act, 2012.
The CEO of the DRAP, Asim Rauf, said that the pharmaceutical companies had violated the goods manufacturing practice.
“The action against these companies was taken on the recommendation of field teams. The inspection found that the companies were involved in substandard drug manufacturing,” he explained.
The CEO stated that ensuring the availability of world-class medicines in the country is the DRAP’s priority. He added that the nationwide action against substandard medicines will continue, and violators will be dealt with strictly.